Partnering

EXOSOMES FOR DRUG DELIVERY

CustomEx^TM: A customisable Exosome Platform

• ReNeuron seeks partnerships with companies developing promising drug candidates who are interested in our CustomEx^TM   Exosome delivery platform.
• Exosomes address delivery challenges for a variety of payloads such as siRNA, mRNA, proteins, and gene editing technologies.
• Using our iPSC platform we have the potential to produce exosomes with tissue specific targeting ability.
• This Technology supported by an extensive Intellectual property portfolio.

For Partnering our CustomEx^TM   Exosome Platform and non-confidential information, please reach out here. 

TECHNOLOGY PARTNERSHIPS

Conditionally immortalized Induced pluripotent stem cell (iPSC) platform

• We have the capability for partnering and the rapid development of new allogeneic cell lines as cell-based therapeutics or for the production of Exosomes with specific tissue targeting tropisms.

For Partnering opportunities and non-confidential information, please reach out here.  

LEGACY ASSETS AVAILABLE FOR PARTNERING

hRPC Program in Retinitis Pigmentosa

• Our human retinal progenitor cell line (hRPC) has been dosed in patients in a Phase 1/2a clinical program in the US. The Company intends to out-license its RP program (outside of China).

CTX Stroke Program

• ReNeuron’s immortalized neural progenitor cell line (CTX) completed a Phase 2 b study in the US as a therapy for the treatment of patients left disabled by a stroke.
  
• This program continues through its partnership with Fosun Pharma in China and is available for out-license outside of China.

For Partnering or further information about these programs including clinical trials please reach out here.